Full-Time

Site Head of Quality

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

Compensation Overview

$186k - $230k/yr

Camarillo, CA, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Quality Assurance (QA)
Microbiology

Get referred to Curia

See people who can refer or advise you

Requirements
  • A Bachelor of Science or Bachelor of Arts degree in a scientific field is required; microbiology is preferred.
  • At least 15 years of progressively greater responsibility in Quality Operations within the pharmaceutical, biologics, or medical device industry, including project, technical, and personnel management experience.
  • Effective communication skills to collaborate with others and proactively resolve obstacles.
  • Must pass a background check.
  • Must pass a drug screen.
  • May be required to pass Occupational Health Screening.
  • May be required to obtain and maintain gowning certification.
  • May be required to obtain and maintain media qualification.
Responsibilities
  • Establish and maintain the site quality system to meet regulatory expectations and current good manufacturing practice requirements across global regions.
  • Provide technical quality oversight and support to the Vice President of Quality Operations in making quality decisions.
  • Ensure manufacturing quality oversight across operations and GMP compliance from material dispensing through final product dispatch.
  • Provide guidance and processes complying with global cross-contamination control requirements.
  • Support plant management on new products and changes to products, processes, and services to achieve a consistent approach to Quality Assurance and Regulatory Affairs.
  • Direct site quality and compliance process improvements and goals using current regulations and demonstrated best practices.
  • Support continuous quality and cost improvement efforts.
  • Ensure Curia global Quality Systems requirements are implemented and maintained throughout the facility.
  • Drive accountability for decisions affecting product and process quality and determine when escalation is needed.
  • Provide leadership, subject matter expertise, and direction to the Quality Organization.
  • Evaluate and recommend solutions and implementation strategies for product and process issues using analytical, technical, and leadership skills.
  • Develop, direct, and manage the Manufacturing Quality Assurance function.
  • Develop, direct, and manage the Quality Control function, including the Microbiology and Chemistry laboratories and environmental monitoring.
  • Develop, direct, and manage the Quality Systems and Compliance function.
  • Develop, direct, and manage the Quality Assurance function.
  • Manage resources to ensure stability testing is completed on time to meet customer requirements.
  • Hire and retain talent and support the career development of the team.
  • Provide plant management with data and information to reduce the potential for regulatory action and support site productivity management.
  • Keep plant management advised of agency, customer, and internal audit compliance commitments.
  • Develop and maintain the site Quality budget.
Desired Qualifications
  • Microbiology specialization or background.

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Albuquerque’s $200 million expansion adds commercial drug-product capacity during 2025-2026.
  • Glasgow’s upgrade reaches early 2027, expanding batches to 20,000 vials.
  • March 2025 refinancing and July 2026 recapitalization inject capital for near-term execution.

What critics are saying

  • Apollo-led recapitalization on July 8, 2026 signals strained leverage and lender control.
  • Curia will close Burlington by June 1, 2026, cutting 81 jobs and shrinking capacity.
  • Octus reported June 2, 2026 out-of-court restructuring talks; a failed process risks insolvency.

What makes Curia unique

  • Curia spans discovery through commercial fill-finish across 20+ sites, rare among CDMOs.
  • Glasgow and Albuquerque expansions deepen sterile injectables capacity, including Annex 1 isolator lines.
  • Hopkinton CLD upgrades deliver sixfold higher titers, strengthening biologics process-development economics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.